Rivaroxaban versus Warfarin for Prevention of Thromboembolism in Bangladeshi Patients with Non-Valvular Atrial Fibrillation

Authors

  • Golam Sodruddin Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Md Mukhlesur Rahman Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • SM Ahsan Habib Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • MSI Tipu Chowdhury Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Adnan Bashar Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Md Harisul Hoque Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka
  • Abdul Wadud Chowdhury Department of Cardiology, Dhaka Medical College Hospital, Dhaka
  • Najnin Akter Department of Anatomy, Brahmanbaria Medical College, Brahmanbaria
  • Shah Md Zakir Hossain Department of Nephrology, BSMMU, Dhaka
  • Sajal Krishna Banerjee Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka

DOI:

https://doi.org/10.3329/uhj.v16i2.49666

Keywords:

Rivaroxaban; Warfarin; Non valvular atrial fibrilation.

Abstract

Background: The use of Warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulant effects than Warfarin.

Methods: In this Open comparison trial, the researchers compared Rivaroxaban (at a daily dose of 20 mg or 15 mg daily in patient with a creatinine clearance of 30-49 ml/min ) with dose adjusted Warfarin (target INR 2.0 to3.0) in 2,846 patients with nonvalvular atrial fibrillation and CHA2DS2-VASc Score 2 or more. The primary efficacy outcome was stroke or systemic embolism and primary safety outcome was major or minor bleeding. This research was designed to determine whether Rivaroxaban have more efficacy and safety than Warfarin for the primary outcomes.

Results: Total follow-up period was 6 months. Risk factors and co-morbidities were similar in both groups. Baseline investigations were also similar. Age and sex of both groups were matched. The rate of ischaemic stroke was 1.8% in Rivaroxaban group, as compared with 2.18% in the Warfarin group (p 0.479, nonsignificant). The rate of haemorrhagic stroke was 0.53% in Rivaroxaban group, as compared with 1.36 % in the Warfarin group (p 0.026, significant). Systemic embolism was 0.08% in Rivaroxaban group, as compared with 0.15 % in the Warfarin group (p 0.561, non-significant). The rate of major bleeding was 0.4% in Rivaroxaban group and 0.53 % in the Warfarin group (p 0.361, non-significant). The rate of minor bleeding was 2.10% in Rivaroxaban group, as compared with 2.33% in the Warfarin group (p 0.681, non-significant).

Conclusions: Rivaroxaban have similar efficacy and better safety profile than Warfarin in patients with nonvalvular atrial fibrillation in Bangladeshi population.

University Heart Journal Vol. 16, No. 2, Jul 2020; 99-105

Downloads

Download data is not yet available.
Abstract
199
PDF
121

Downloads

Published

2020-10-11

How to Cite

Sodruddin, G., Rahman, M. M., Habib, S. A., Chowdhury, M. T., Bashar, A., Hoque, M. H., Chowdhury, A. W., Akter, N., Hossain, S. M. Z., & Banerjee, S. K. (2020). Rivaroxaban versus Warfarin for Prevention of Thromboembolism in Bangladeshi Patients with Non-Valvular Atrial Fibrillation. University Heart Journal, 16(2), 99–105. https://doi.org/10.3329/uhj.v16i2.49666

Issue

Section

Original Articles